XFOR$3.160.32%-0.010
X 4 Pharmaceuticals Inc (XFOR)
Date: 2026-11-04 16:00O: 3.30H: 3.36L: 3.10C: 3.23Vol: 208.4k
X 4 Pharmaceuticals Inc stock is traded at $3.16, with a volume of 145,403. It is down -0.32% in the last 24 hours and up +11.66% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Previous Close:
$3.17
Open:
$3.30
24h Volume:
145,403
Relative Volume:
0.20
Market Cap:
$313.30M
Revenue:
$9.01M
Net Income/Loss:
-$99.72M
P/E Ratio:
-
EPS:
-$4.54
Net Cash Flow:
-$92.85M
1W Performance:
-5.67%
1M Performance:
+11.66%
6M Performance:
-24.94%
1Y Performance:
-20.40%
1-Day Range:
$3.10$3.36
1-Week Range:
$3.05$3.49
52-Week Range:
$2.43$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
857-529-8300Address
61 NORTH BEACON STREET, BOSTON, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
- Craig Adam ROct 16 '26Executive Chairman
- Transaction
- Buy
- Cost
- $2.58
- #Shares
- 4,600
- Value ($)
- 11,884
- #Shares Total
- 333,251
- KIRSKE DAVIDOct 01 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $2.86
- #Shares
- 11,767
- Value ($)
- 33,658
- #Shares Total
- 155,983
- David KirskeOct 01 '26Officer
- Transaction
- Proposed Sale
- Cost
- $2.86
- #Shares
- 11,767
- Value ($)
- 33,658
- #Shares Total
- 0
- Adam CraigAug 12 '26Executive Chaiman
- Transaction
- Proposed Sale
- Cost
- $4.56
- #Shares
- 47,436
- Value ($)
- 216,071
- #Shares Total
- 0
- Volpone JohnAug 12 '26President
- Transaction
- Sale
- Cost
- $4.44
- #Shares
- 24,576
- Value ($)
- 109,228
- #Shares Total
- 265,305
- Craig Adam RAug 12 '26Executive Chairman
- Transaction
- Sale
- Cost
- $4.44
- #Shares
- 47,436
- Value ($)
- 210,829
- #Shares Total
- 328,651
- John VolponeAug 12 '26Officer
- Transaction
- Proposed Sale
- Cost
- $4.55
- #Shares
- 24,576
- Value ($)
- 111,944
- #Shares Total
- 0
- KIRSKE DAVIDJun 30 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $4.26
- #Shares
- 8,543
- Value ($)
- 36,428
- #Shares Total
- 167,750
- David KirskeMay 12 '26Officer
- Transaction
- Proposed Sale
- Cost
- $4.29
- #Shares
- 16,961
- Value ($)
- 72,820
- #Shares Total
- 0
- KIRSKE DAVIDMay 12 '26Chief Financial Officer
- Transaction
- Sale
- Cost
- $4.29
- #Shares
- 16,961
- Value ($)
- 72,820
- #Shares Total
- 176,293
